Patent Exclusivity Health Checks for Small Molecules: Are Your U.S. Patents Ready to Maximize ROI?
March 8, 2018
Webinar
Strafford Publications
As part of Strafford Publications' webinar series, Finnegan partners Shana Cyr, Mark Feldstein, Tom Irving, and John Livingstone will discuss health checks on U.S. patent exclusivity for small molecules in Phase II efficacy trials and proceeding through large-scale randomized Phase III clinical trials. The program will also consider submission of the NDA and subsequent approval and marketing. For more information, or to register, please see Strafford Publications' website.
